Fecal microbiota transplantation in cancer management: Current status and perspectives

Danfeng Chen, Jingyi Wu, Duochen Jin, Bangmao Wang, Hailong Cao, Danfeng Chen, Jingyi Wu, Duochen Jin, Bangmao Wang, Hailong Cao

Abstract

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer-treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

Keywords: cancer; dysbiosis; fecal microbiota transplantation; gut microbiota; therapy.

© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Figures

Figure 1
Figure 1
Management of cancer by fecal microbiota transplant. FMT represents a potential therapeutic strategy for cancer by reconstruction of intestinal microbiota, amelioration of bile acid metabolism and modulation of immunotherapy efficacy. Various factors such as host genetics, diet, antibiotics and stress could lead to alterations of gut microbiota, named as gut dysbiosis. Microbial dysbiosis and special bacteria in the gut are capable of affecting cancer development and progression via activating tumorigenic pathway, inducing inflammation and damaging host DNA. Special bacterial products, such as FadA toxin from Fusobacterium nucleatum, CagA protein from Helicobacter pylori, AvrA protein from S. enterica Typhi, and BFT from Enterotoxigenic Bacteroides fragilis can promote the separation of β‐catenin from E‐cadherin, which can trigger β‐catenin activation and contribute to tumorigenesis. The beneficial component in bacterial metabolites, such as SCFAs, is also decreased in microbial dysbiosis. Intestinal dysbiosis may be conducive to bacterial translocation, exerting pro‐inflammatory effects, which is mediated by MAMPs that activate TLRs in macrophages and dendritic cells. TLR signaling promotes the expression of the pro‐inflammatory factors, including IL‐23, TNF and IL‐1, thereby promoting carcinogenesis. Several microbial metabolites can directly or indirectly damage host DNA, fueling carcinogenesis. Special microbial toxins (CDT and colibactin) could directly induce DNA damage. Furthermore, gut bacteria also damage DNA indirectly via polyamines, DCA, ROS, RNS and H2S. FMT, fecal microbiota transplantation; BFT, Bacteroides fragilis toxin; SCFAs, short‐chain fatty acids; MAMP, microbe‐associated molecular pattern; TLR, Toll‐like receptor; IL‐23, interleukin 23; TNF, tumor necrosis factor; IL‐1, interleukin; Th17, T helper 17; STAT3, signal transducer and activator of transcription 3; NF‐κB, nuclear factor‐κB; CDT, cytolethal distending toxins; DCA, deoxycholic acid; H2S, hydrogen sulphide; RNS, reactive nitrogen species; ROS, reactive oxygen species. [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016;164:337–40.
    1. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489:220–30.
    1. Wang L, Cao H, Liu L, et al. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a lactobacillus rhamnosus GG‐derived protein. J Biol Chem 2014;289:20234–44.
    1. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016;16:341–52.
    1. Cao H, Liu X, An Y, et al. Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine. Sci Rep 2017;7:10322.
    1. Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016;22:1079–89.
    1. Mima K, Nakagawa S, Sawayama H, et al. The microbiome and hepatobiliary‐pancreatic cancers. Cancer Lett 2017;402:9–15.
    1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–79.
    1. Arthur JC, Perez‐Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer‐inducing activity of the microbiota. Science 2012;338:120–3.
    1. Khan S. Potential role of Escherichia coli DNA mismatch repair proteins in colon cancer. Crit Rev Oncol Hematol 2015;96:475–82.
    1. Khan S, Zakariah M, Rolfo C, et al. Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology. Oncotarget 2017;8:30830–43.
    1. Khan S, Zakariah M, Palaniappan S. Computational prediction of mycoplasma hominis proteins targeting in nucleus of host cell and their implication in prostate cancer etiology. Tumour Biol 2016;37:10805–13.
    1. Khan S, Imran A, Khan AA, et al. Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer. PLoS One 2016;11:e0148530.
    1. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407–15.
    1. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044–9.
    1. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700‐year‐old fecal microbiota transplantation. Am J Gastroenterol 2012;107:1755–6.
    1. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854–9.
    1. Schwan A, Sjölin S, Trottestam U, et al. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983;2:845.
    1. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–98. quiz 499.
    1. Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra‐gastrointestinal diseases. J Physiol Pharmacol 2015;66:483–91.
    1. Xu MQ, Cao HL, Wang WQ, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol 2015;21:102–11.
    1. Costello SP, Soo W, Bryant RV, et al. Systematic review with meta‐analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther 2017;46:213–24.
    1. Mullish BH, Quraishi MN, Segal JP, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2018;67:1920–41.
    1. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015;149:223–37.
    1. Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long‐term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther 2015;42:1011–8.
    1. Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid‐gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 2015;30:51–8.
    1. Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection ‐ fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther 2017;45:899–908.
    1. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014;48:693–702.
    1. Kao D, Roach B, Silva M, et al. Effect of Oral capsule‐ vs colonoscopy‐delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017;318:1985–93.
    1. Distrutti E, Monaldi L, Ricci P, et al. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol 2016;22:2219–41.
    1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569–80.
    1. Terveer EM, van Beurden YH, Goorhuis A, et al. Faecal microbiota transplantation in clinical practice. Gut 2018;67:196.
    1. Shahanavaj K, Gil‐Bazo I, Castiglia M, et al. Cancer and the microbiome: potential applications as new tumor biomarker. Expert Rev Anticancer Ther 2015;15:317–30.
    1. Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527–39.
    1. Lam SY, Yu J, Wong SH, et al. The gastrointestinal microbiota and its role in oncogenesis. Best Pract Res Clin Gastroenterol 2017;31:607–18.
    1. Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 2018;359:1366–70.
    1. Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early‐stage detection of colorectal cancer. Mol Syst Biol 2014;10:766.
    1. Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018;67:1024–32.
    1. Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ‐free and conventional mice. Gastroenterology 2017;153:1621–33.e6.
    1. Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 2016;65:1906–15.
    1. Dik VK, van Oijen MG, Smeets HM, et al. Frequent use of antibiotics is associated with colorectal cancer risk: results of a nested case‐control study. Dig Dis Sci 2016;61:255–64.
    1. Boursi B, Haynes K, Mamtani R, et al. Impact of antibiotic exposure on the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2015;24:534–42.
    1. Wang JL, Chang CH, Lin JW, et al. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case‐control study in patients with type 2 diabetes mellitus. Int J Cancer 2014;135:956–67.
    1. Cao Y, Wu K, Mehta R, et al. Long‐term use of antibiotics and risk of colorectal adenoma. Gut 2018;67:672–8.
    1. Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation‐‐another step in understanding the role of the human microbiota. Eur J Cancer 2015;51:2655–64.
    1. Kaur K, Saxena A, Debnath I, et al. Antibiotic‐mediated bacteriome depletion in ApcMin/+ mice is associated with reduction in mucus‐producing goblet cells and increased colorectal cancer progression. Cancer Med 2018;7:2003–12.
    1. Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017;358:1443–8.
    1. Johnson CH, Dejea CM, Edler D, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab 2015;21:891–7.
    1. Ijssennagger N, Belzer C, Hooiveld GJ, et al. Gut microbiota facilitates dietary heme‐induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci USA 2015;112:10038–43.
    1. Schulz MD, Atay C, Heringer J, et al. High‐fat‐diet‐mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature 2014;514:508–12.
    1. Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 2018;155:33–7.e6.
    1. Cao H, Xu M, Dong W, et al. Secondary bile acid‐induced dysbiosis promotes intestinal carcinogenesis. Int J Cancer 2017;140:2545–56.
    1. Gagnaire A, Nadel B, Raoult D, et al. Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol 2017;15:109–28.
    1. Wang F, Meng W, Wang B, et al. Helicobacter pylori‐induced gastric inflammation and gastric cancer. Cancer Lett 2014;345:196–202.
    1. Odenbreit S, Püls J, Sedlmaier B, et al. Translocation of helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000;287:1497–500.
    1. Yong X, Tang B, Li BS, et al. Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways. Cell Commun Signal 2015;13:30.
    1. Ricci V. Relationship between VacA toxin and host cell autophagy in helicobacter pylori infection of the human stomach: A few answers, many questions. Toxins (Basel) 2016;8(7):203.
    1. Mashima H, Suzuki J, Hirayama T, et al. Involvement of vesicle‐associated membrane protein 7 in human gastric epithelial cell vacuolation induced by helicobacter pylori‐produced VacA. Infect Immun 2008;76:2296–303.
    1. Boleij A, Hechenbleikner EM, Goodwin AC, et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 2015;60:208–15.
    1. Boleij A, Tjalsma H. The itinerary of streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis 2013;13:719–24.
    1. Kumar R, Herold JL, Schady D, et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog 2017;13:e1006440.
    1. Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 2014;20:859–67.
    1. Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll‐like receptor 4 signaling to nuclear factor‐κB, and up‐regulating expression of MicroRNA‐21. Gastroenterology 2017;152:851–66.e24.
    1. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E‐cadherin/β‐catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195–206.
    1. Abed J, Emgård JE, Zamir G, et al. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor‐expressed gal‐GalNAc. Cell Host Microbe 2016;20:215–25.
    1. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes Chemoresistance to colorectal cancer by modulating autophagy. Cell 2017;170:548–63.e16.
    1. Xie YH, Gao QY, Cai GX, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine 2017;25:32–40.
    1. Wong SH, Tny K, Chow TC, et al. Quantitation of faecal fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut 2017;66:1441–8.
    1. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971–6.
    1. Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide‐induced therapeutic immunomodulatory effects. Immunity 2016;45:931–43.
    1. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti‐PD‐1 immunotherapy in melanoma patients. Science 2018;359:97–103.
    1. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti‐PD‐L1 efficacy. Science 2015;350:1084–9.
    1. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA‐4 blockade relies on the gut microbiota. Science 2015;350:1079–84.
    1. Routy B, Le CE, Derosa L, et al. Gut microbiome influences efficacy of PD‐1‐based immunotherapy against epithelial tumors. Science 2018;359:91–7.
    1. Whiteside SA, Razvi H, Dave S, et al. The microbiome of the urinary tract‐‐a role beyond infection. Nat Rev Urol 2015;12:81–90.
    1. Dias‐Jácome E, Libânio D, Borges‐Canha M, et al. Gastric microbiota and carcinogenesis: the role of non‐helicobacter pylori bacteria ‐ a systematic review. Rev Esp Enferm Dig 2016;108:530–40.
    1. Hsieh YY, Tung SY, Pan HY, et al. Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep 2018;8:158.
    1. Ferreira RM, Pereira‐Marques J, Pinto‐Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer‐associated microbiota. Gut 2018;67:226–36.
    1. Shah MA. Gastric cancer: the gastric microbiota ‐ bacterial diversity and implications. Nat Rev Gastroenterol Hepatol 2017;14:692–3.
    1. Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut 2018;67:2092–2096.
    1. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of Metachronous gastric cancer. N Engl J Med 2018;378:1085–95.
    1. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006;12:782–6.
    1. Wu S, Powell J, Mathioudakis N, et al. Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin‐8 through mitogen‐activated protein kinases and a tyrosine kinase‐regulated nuclear factor‐kappaB pathway. Infect Immun 2004;72:5832–9.
    1. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016–22.
    1. Tsoi H, Esh C, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017;152:1419–33.e5.
    1. Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non‐invasive biomarkers for colorectal cancer. Gut 2017;66:70–8.
    1. Chen ZF, Ai LY, Wang JL, et al. Probiotics clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol 2015;10:1433–45.
    1. Jacouton E, Chain F, Sokol H, et al. Probiotic strain lactobacillus casei BL23 prevents colitis‐associated colorectal cancer. Front Immunol 2017;8:1553.
    1. Zhang JW, Du P, Gao J, et al. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci 2012;343:199–205.
    1. Liang S, Xu L, Zhang D, et al. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol 2016;27:227–32.
    1. Rosshart SP, Vassallo BG, Angeletti D, et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 2017;171:1015–28.e13.
    1. Malhi H, Camilleri M. Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases. Curr Opin Pharmacol 2017;37:80–6.
    1. Ma C, Han M, Heinrich B, et al. Gut microbiome‐mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018;360(6391):eaan5931.
    1. Segura‐López FK, Güitrón‐Cantú A, Torres J. Association between helicobacter spp. infections and hepatobiliary malignancies: a review. World J Gastroenterol 2015;21:1414–23.
    1. De Minicis S, Rychlicki C, Agostinelli L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014;59:1738–49.
    1. Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016;65:830–9.
    1. Qin C, Zhang H, Zhao L, et al. Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. Sci China Life Sci 2017. [in press].
    1. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014;147:1327–37.e3.
    1. Han SH, Suk KT, Kim DJ, et al. Effects of probiotics (cultured lactobacillus subtilis/streptococcus faecium) in the treatment of alcoholic hepatitis: randomized‐controlled multicenter study. Eur J Gastroenterol Hepatol 2015;27:1300–6.
    1. Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high‐fat diet‐induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 2017;7:1529.
    1. Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol‐induced liver injury in mice. J Hepatol 2017;66:806–15.
    1. Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid‐ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017;15:600–2.
    1. Philips CA, Phadke N, Ganesan K, et al. Healthy donor faecal transplant for corticosteroid nonresponsive severe alcoholic hepatitis. BMJ Case Rep 2017;2017:bcr‐2017–222310.
    1. Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy. Hepatology 2017;65:1765–8.
    1. Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic‐associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology 2018;68(4):1549–1558.
    1. Wang WW, Zhang Y, Huang XB, et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride‐induced acute hepatic dysfunction. World J Gastroenterol 2017;23:6983–94.
    1. Kao D, Roach B, Park H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology 2016;63:339–40.
    1. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017;66:1727–38.
    1. Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis 2013;34:2193–7.
    1. Ochi A, Nguyen AH, Bedrosian AS, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 2012;209:1671–87.
    1. Geller LT, Barzily‐Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017;357:1156–60.
    1. Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population‐based nested case‐control study. Gut 2018;67:120–7.
    1. Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015;6:7209–20.
    1. Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 2018;8:403–16.
    1. Hill MJ, Goddard P, Williams RE. Gut bacteria and aetiology of cancer of the breast. Lancet 1971;2:472–3.
    1. Goedert JJ, Hua X, Bielecka A, et al. Postmenopausal breast cancer and oestrogen associations with the IgA‐coated and IgA‐noncoated faecal microbiota. Br J Cancer 2018;118:471–9.
    1. Yang J, Tan Q, Fu Q, et al. Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. Breast Cancer 2017;24:220–8.
    1. Maroof H, Hassan ZM, Mobarez AM, et al. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012;32:1353–9.
    1. Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased Metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 2017;19:848–55.
    1. Mullard A. Oncologists tap the microbiome in bid to improve immunotherapy outcomes. Nat Rev Drug Discov 2018;17:153–5.
    1. Kim JS, Ward KK, Shah NR, et al. Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad‐spectrum antibiotics. Support Care Cancer 2013;21:3103–7.
    1. Hefazi M, Patnaik MM, Hogan WJ, et al. Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: a single‐institution retrospective case series. Mayo Clin Proc 2017;92:1617–24.
    1. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014;109:1065–71.
    1. Blackburn LM, Bales A, Caldwell M, et al. Fecal microbiota transplantation in patients with cancer undergoing treatment. Clin J Oncol Nurs 2015;19:111–4.
    1. Trubiano JA, George A, Barnett J, et al. A different kind of "allogeneic transplant": successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B‐cell lymphoma. Leuk Lymphoma 2015;56:512–4.
    1. Mittal C, Miller N, Meighani A, et al. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B‐cell lymphoma. Bone Marrow Transplant 2015;50:1010.
    1. Neemann K, Eichele DD, Smith PW, et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis 2012;14:E161–5.
    1. de Castro CG, Ganc AJ, Ganc RL, et al. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant 2015;50:145.
    1. Webb BJ, Brunner A, Ford CD, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2016;18:628–33.
    1. Innes AJ, Mullish BH, Fernando F, et al. Faecal microbiota transplant: a novel biological approach to extensively drug‐resistant organism‐related non‐relapse mortality. Bone Marrow Transplant 2017;52:1452–4.
    1. Gerassy‐Vainberg S, Blatt A, Danin‐Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut 2018;67:97–107.
    1. Cui M, Xiao H, Li Y, et al. Faecal microbiota transplantation protects against radiation‐induced toxicity. EMBO Mol Med 2017;9:448–61.
    1. Staffas A, Dsm B, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft‐versus‐host disease. Blood 2017;129:927–33.
    1. Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014;124:1174–82.
    1. Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid‐resistant acute graft‐versus‐host disease of the gut. Blood 2016;128:2083–8.
    1. Amirtha T. MICROBIOME RESEARCH. Banking on stool despite an uncertain future. Science 2016;352:1261–2.
    1. Olesen SW, Leier MM, Alm EJ, et al. Searching for superstool: maximizing the therapeutic potential of FMT. Nat Rev Gastroenterol Hepatol 2018;15:387–8.
    1. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One 2016;11:e0161174.
    1. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013;108:1367.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe